Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 Pathways for treatment of lung cancer and hnscc

Katherine R. Singleton, Trista K. Hinz, Emily K. Kleczko, A. Lindsay Marek, Jeff Kwak, Taylor Harp, Jihye Kim, Aik-Choon Tan, Lynn E. Heasley

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

The FGFR1 is a therapeutic target under investigation in multiple solid tumors and clinical trials of selective tyrosine kinase inhibitors (TKI) are underway. Treatment with a single TKI represents a logical step toward personalized cancer therapy, but intrinsic and acquired resistance mechanisms limit their long-term benefit. In this study, we deployed RNAi-based functional genomic screens to identify protein kinases controlling the intrinsic sensitivity of FGFR1-dependent lung cancer and head and neck squamous cell cancer (HNSCC) cells to ponatinib, a multikinase FGFR-Active inhibitor. We identified and validated a synthetic lethal interaction between MTOR and ponatinib in non-small cell lung carcinoma cells. In addition, treatment with MTOR-targeting shRNAs and pharmacologic inhibitors revealed that MTOR is an essential protein kinase in other FGFR1-expressing cancer cells. The combination of FGFR inhibitors and MTOR or AKT inhibitors resulted in synergistic growth suppression in vitro. Notably, tumor xenografts generated from FGFR1-dependent lung cancer cells exhibited only modest sensitivity to monotherapy with the FGFRspecific TKI, AZD4547, but when combined with the MTOR inhibitor, AZD2014, significantly attenuated tumor growth and prolonged survival. Our findings support the existence of a signaling network wherein FGFR1-driven ERK and activated MTOR/AKT represent distinct arms required to induce full transformation. Furthermore, they suggest that clinical efficacy of treatments for FGFR1-driven lung cancers and HNSCC may be achieved by combining MTOR inhibitors and FGFR-specific TKIs.

Original languageEnglish
Pages (from-to)4398-4406
Number of pages9
JournalCancer Research
Volume75
Issue number20
DOIs
Publication statusPublished - 2015 Oct 15
Externally publishedYes

Fingerprint

RNA Interference
Lung Neoplasms
Head and Neck Neoplasms
Protein-Tyrosine Kinases
Squamous Cell Neoplasms
Neoplasms
Protein Kinases
Growth
Heterografts
Non-Small Cell Lung Carcinoma
Arm
Clinical Trials
Therapeutics
ponatinib

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Singleton, K. R., Hinz, T. K., Kleczko, E. K., Marek, A. L., Kwak, J., Harp, T., ... Heasley, L. E. (2015). Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 Pathways for treatment of lung cancer and hnscc. Cancer Research, 75(20), 4398-4406. https://doi.org/10.1158/0008-5472.CAN-15-0509

Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 Pathways for treatment of lung cancer and hnscc. / Singleton, Katherine R.; Hinz, Trista K.; Kleczko, Emily K.; Marek, A. Lindsay; Kwak, Jeff; Harp, Taylor; Kim, Jihye; Tan, Aik-Choon; Heasley, Lynn E.

In: Cancer Research, Vol. 75, No. 20, 15.10.2015, p. 4398-4406.

Research output: Contribution to journalArticle

Singleton, KR, Hinz, TK, Kleczko, EK, Marek, AL, Kwak, J, Harp, T, Kim, J, Tan, A-C & Heasley, LE 2015, 'Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 Pathways for treatment of lung cancer and hnscc', Cancer Research, vol. 75, no. 20, pp. 4398-4406. https://doi.org/10.1158/0008-5472.CAN-15-0509
Singleton, Katherine R. ; Hinz, Trista K. ; Kleczko, Emily K. ; Marek, A. Lindsay ; Kwak, Jeff ; Harp, Taylor ; Kim, Jihye ; Tan, Aik-Choon ; Heasley, Lynn E. / Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 Pathways for treatment of lung cancer and hnscc. In: Cancer Research. 2015 ; Vol. 75, No. 20. pp. 4398-4406.
@article{856fc67769b1437aa299af6f00ba9221,
title = "Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 Pathways for treatment of lung cancer and hnscc",
abstract = "The FGFR1 is a therapeutic target under investigation in multiple solid tumors and clinical trials of selective tyrosine kinase inhibitors (TKI) are underway. Treatment with a single TKI represents a logical step toward personalized cancer therapy, but intrinsic and acquired resistance mechanisms limit their long-term benefit. In this study, we deployed RNAi-based functional genomic screens to identify protein kinases controlling the intrinsic sensitivity of FGFR1-dependent lung cancer and head and neck squamous cell cancer (HNSCC) cells to ponatinib, a multikinase FGFR-Active inhibitor. We identified and validated a synthetic lethal interaction between MTOR and ponatinib in non-small cell lung carcinoma cells. In addition, treatment with MTOR-targeting shRNAs and pharmacologic inhibitors revealed that MTOR is an essential protein kinase in other FGFR1-expressing cancer cells. The combination of FGFR inhibitors and MTOR or AKT inhibitors resulted in synergistic growth suppression in vitro. Notably, tumor xenografts generated from FGFR1-dependent lung cancer cells exhibited only modest sensitivity to monotherapy with the FGFRspecific TKI, AZD4547, but when combined with the MTOR inhibitor, AZD2014, significantly attenuated tumor growth and prolonged survival. Our findings support the existence of a signaling network wherein FGFR1-driven ERK and activated MTOR/AKT represent distinct arms required to induce full transformation. Furthermore, they suggest that clinical efficacy of treatments for FGFR1-driven lung cancers and HNSCC may be achieved by combining MTOR inhibitors and FGFR-specific TKIs.",
author = "Singleton, {Katherine R.} and Hinz, {Trista K.} and Kleczko, {Emily K.} and Marek, {A. Lindsay} and Jeff Kwak and Taylor Harp and Jihye Kim and Aik-Choon Tan and Heasley, {Lynn E.}",
year = "2015",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-15-0509",
language = "English",
volume = "75",
pages = "4398--4406",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Kinome RNAi screens reveal synergistic targeting of MTOR and FGFR1 Pathways for treatment of lung cancer and hnscc

AU - Singleton, Katherine R.

AU - Hinz, Trista K.

AU - Kleczko, Emily K.

AU - Marek, A. Lindsay

AU - Kwak, Jeff

AU - Harp, Taylor

AU - Kim, Jihye

AU - Tan, Aik-Choon

AU - Heasley, Lynn E.

PY - 2015/10/15

Y1 - 2015/10/15

N2 - The FGFR1 is a therapeutic target under investigation in multiple solid tumors and clinical trials of selective tyrosine kinase inhibitors (TKI) are underway. Treatment with a single TKI represents a logical step toward personalized cancer therapy, but intrinsic and acquired resistance mechanisms limit their long-term benefit. In this study, we deployed RNAi-based functional genomic screens to identify protein kinases controlling the intrinsic sensitivity of FGFR1-dependent lung cancer and head and neck squamous cell cancer (HNSCC) cells to ponatinib, a multikinase FGFR-Active inhibitor. We identified and validated a synthetic lethal interaction between MTOR and ponatinib in non-small cell lung carcinoma cells. In addition, treatment with MTOR-targeting shRNAs and pharmacologic inhibitors revealed that MTOR is an essential protein kinase in other FGFR1-expressing cancer cells. The combination of FGFR inhibitors and MTOR or AKT inhibitors resulted in synergistic growth suppression in vitro. Notably, tumor xenografts generated from FGFR1-dependent lung cancer cells exhibited only modest sensitivity to monotherapy with the FGFRspecific TKI, AZD4547, but when combined with the MTOR inhibitor, AZD2014, significantly attenuated tumor growth and prolonged survival. Our findings support the existence of a signaling network wherein FGFR1-driven ERK and activated MTOR/AKT represent distinct arms required to induce full transformation. Furthermore, they suggest that clinical efficacy of treatments for FGFR1-driven lung cancers and HNSCC may be achieved by combining MTOR inhibitors and FGFR-specific TKIs.

AB - The FGFR1 is a therapeutic target under investigation in multiple solid tumors and clinical trials of selective tyrosine kinase inhibitors (TKI) are underway. Treatment with a single TKI represents a logical step toward personalized cancer therapy, but intrinsic and acquired resistance mechanisms limit their long-term benefit. In this study, we deployed RNAi-based functional genomic screens to identify protein kinases controlling the intrinsic sensitivity of FGFR1-dependent lung cancer and head and neck squamous cell cancer (HNSCC) cells to ponatinib, a multikinase FGFR-Active inhibitor. We identified and validated a synthetic lethal interaction between MTOR and ponatinib in non-small cell lung carcinoma cells. In addition, treatment with MTOR-targeting shRNAs and pharmacologic inhibitors revealed that MTOR is an essential protein kinase in other FGFR1-expressing cancer cells. The combination of FGFR inhibitors and MTOR or AKT inhibitors resulted in synergistic growth suppression in vitro. Notably, tumor xenografts generated from FGFR1-dependent lung cancer cells exhibited only modest sensitivity to monotherapy with the FGFRspecific TKI, AZD4547, but when combined with the MTOR inhibitor, AZD2014, significantly attenuated tumor growth and prolonged survival. Our findings support the existence of a signaling network wherein FGFR1-driven ERK and activated MTOR/AKT represent distinct arms required to induce full transformation. Furthermore, they suggest that clinical efficacy of treatments for FGFR1-driven lung cancers and HNSCC may be achieved by combining MTOR inhibitors and FGFR-specific TKIs.

UR - http://www.scopus.com/inward/record.url?scp=84945556079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945556079&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-0509

DO - 10.1158/0008-5472.CAN-15-0509

M3 - Article

VL - 75

SP - 4398

EP - 4406

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 20

ER -